JIM
SUPN icon

Jupiter Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Jupiter Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14,672
Closed -$632K – 448
2017
Q2 		$632K Sell
14,672
-38,066
-72% -$1.35M 0.01% 297
2017
Q1 		$1.65M Buy
+52,738
New +$1.41M 0.02% 216
2016
Q2 		– Sell
-47,534
Closed -$724K – 519
2016
Q1 		$724K Buy
+47,534
New +$620K 0.01% 339

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Jupiter Investment Management's SUPN Position: Q3 2017 in Review

Jupiter Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 14,672 shares — an estimated $632K sold.

Jupiter Investment Management first reported a position in SUPN in Q1 2016 and held it in 3 quarters. The position peaked at $1.65M in Q1 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

  • Jupiter Investment Management reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Jupiter Investment Management sold 14,672 Supernus Pharmaceuticals shares in Q3 2017, an estimated $632K.
  • Jupiter Investment Management first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 3 quarters.
  • Jupiter Investment Management's Supernus Pharmaceuticals position peaked at $1.65M in Q1 2017.
  • 275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Jupiter Investment Management's 13F filing for Q3 2017, filed 1 Nov 2017.